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To determine whether maternal placental malaria is
associated with an increased risk for perinatal mother-to-
child HIV transmission (MTCT), we studied HIV-positive
women in western Kenya. We enrolled 512 mother-infant
pairs; 128 (25.0%) women had placental malaria, and 102
(19.9%) infants acquired HIV perinatally. Log10 HIV viral
load and episiotomy or perineal tear were associated with
increased perinatal HIV transmission, whereas low-density
placental malaria (<10,000 parasites/µL) was associated
with reduced risk (adjusted relative risk [ARR] 0.4). Among
women dually infected with malaria and HIV, high-density
placental malaria (>10,000 parasites/µL) was associated
with increased risk for perinatal MTCT (ARR 2.0), com-
pared to low-density malaria. The interaction between pla-
cental malaria and MTCT appears to be variable and
complex: placental malaria that is controlled at low density
may cause an increase in broad-based immune responses
that protect against MTCT; uncontrolled, high-density
malaria may simultaneously disrupt placental architecture
and generate substantial antigen stimulus to HIV replica-
tion and increase risk for MTCT.
M
alaria during pregnancy is a serious problem in sub-
Saharan Africa, affecting an estimated 24 million
pregnant women; malaria prevalence may exceed 50%
among primigravid and secundigravid women in malaria-
endemic areas (1). During the past 2 decades, HIV and
AIDS have emerged as major problems in many malaria-
endemic areas of sub-Saharan Africa, where an estimated
28 million persons are infected with HIV (2). Sub-Saharan
Africa accounts for more than two thirds of the world’s 40
million HIV-infected persons and 80% of the world’s HIV-
infected women, with HIV prevalence rates sometimes
exceeding 40% among pregnant women (3). Without inter-
vention, as many as 30%–45% of pregnant women infect-
ed with HIV will pass the virus to their children through
mother-to-child transmission (MTCT) (4), of which
15%–30% is intrauterine or intrapartum.
Given the wide overlap between areas where HIV and
malaria are each prevalent, the epidemic of HIV/AIDS in
areas where Plasmodium falciparum is endemic has gener-
ated concern about potential interactions between the two
infections, especially in sub-Saharan Africa (5–9). Studies
have shown increased HIV replication both in blood
mononuclear cells exposed to malaria antigens in vitro
(10) and in transgenic mice infected with P. chabaudi (11).
Proviral loads are also higher among HIV-infected persons
with clinical malaria compared to those without malaria;
these levels remain high for at least 4 weeks after treatment
(12). Although malaria may increase viral replication in
the short term, the concern that the malaria-associated
increase in viral replication may accelerate HIV disease
progression has not been proven (13). 
Studies among pregnant women in sub-Saharan Africa
have provided the first evidence of an important public
health problem arising from the interaction of HIV and
malaria. HIV infection appears to impair malarial immuni-
ty among pregnant women, as pregnant women infected
with HIV demonstrate more frequent and higher density
parasitemia than pregnant women not infected with HIV
(5–7,14). More recent case-control (15) and longitudinal
(16,17) studies on the clinical pattern of malaria in HIV-
infected, nonpregnant women have shown HIV infection
to be associated with an increased frequency of clinical
malaria and parasitemia, particularly among persons with
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gested that infants exposed in utero to both placental
malaria and maternal HIV infection have an increased risk
for postneonatal death three- to eightfold higher than
infants born to mothers with either infection alone. We
examined the relationship between placental malaria and
perinatal HIV transmission in an area of western Kenya
with high prevalence of malaria and HIV infection.
Participants and Methods 
Study Site
This study was conducted at Nyanza Provincial
General Hospital (NPGH), a large publicly funded hospi-
tal in Kisumu (population 300,000) in western Kenya.
Malaria transmission within Kisumu town is perennial,
and P. falciparum is the predominant species, accounting
for 98% of malaria cases (19). Chloroquine resistance is
prevalent in the area: 75%–80% of P. falciparum strains
show a RII/RIII resistance pattern (20). The prevalence of
HIV infection among pregnant women is approximately
25% (6,21). 
Recruitment and Follow-up
Pregnant women were enrolled from June 1996 through
May 2000. Screening procedures have been described pre-
viously (21). Briefly, women at the antenatal clinic were
eligible for participation if they had an uncomplicated sin-
gleton pregnancy of >32 weeks’ gestation (based on the
fundal height estimation), resided within the Kisumu
municipality, and had no known underlying chronic ill-
ness. Following informed consent, a structured question-
naire was administered in the local language (Dholuo or
Kiswahili) to obtain information on sociodemographic,
health, and obstetric factors. 
A trained HIV counselor then counseled each woman,
and a posttest counseling appointment was made. A blood
sample was taken for HIV antibody testing, hemoglobin
level, and malaria thick blood film. All screened women
were encouraged to deliver at NPGH. In addition, non-
screened women who delivered at NGPH were eligible for
participation if they met study inclusion criteria. Routine
use of zidovudine or nevirapine was not the Kenyan
Ministry of Health policy during the study period, and these
drugs were not available in Ministry of Health facilities.  
At delivery, information was collected on mode and
outcome of delivery and any illness and treatment in the
previous 2 weeks. Within 24 hours of birth, infants were
weighed (±1 g) on an electronic balance (Ohaus, Florham
Park, NJ), and gestational age was assessed by using the
Ballard method (22). All live, singleton, vaginally deliv-
ered infants of HIV-positive mothers were eligible for
study. Infants were seen monthly until 12 months of age. 
Informed consent was obtained from all women before
they were enrolled in this study. Human subjects guide-
lines of the Centers for Disease Control and Prevention
(CDC) and the Kenya Medical Research Institute ethical
review committee were strictly followed. Mothers of
enrolled infants signed an additional informed consent
form for infant participation. 
Ethical Review
The study protocol was approved in 1995 by the institu-
tional review boards of the Kenya Medical Research
Institute; CDC, Atlanta, Georgia, USA; and the Academic
Medical Center (AMC), University of Amsterdam,
Amsterdam, The Netherlands, and was reviewed annually
by the participating institutions. This study occurred during
a changing environment in preventing perinatal HIV trans-
mission, with results of studies in other countries demon-
strating the benefits of short-course AZT use (23,24) or
nevirapine use (25) in late pregnancy and perinatally to
reduce the risk for MTCT. Similarly, studies of malaria pre-
vention in pregnancy during the study interval were demon-
strating the benefit of intermittent antimalarial treatment to
prevent maternal anemia and low birth weight (6,26). The
participating institutions and the Kenyan Ministry of Health
were engaged in discussions about these findings regarding
the ethical considerations for this investigation. The study
continued with full ethical approvals during these discus-
sions. Investigators and institutions have supported the
transition to a system that supports providing intermittent
preventive antimalarial therapy during pregnancy, accord-
ing to the adopted Kenyan national policy. The MTCT pre-
vention program now offers HIV counseling and testing,
community education, and antiretroviral drugs to prevent
MTCT in the study setting (4).
Blood Sampling and Laboratory Procedures  
At delivery, maternal peripheral and placental thick
blood films were prepared, stained with 10% Giemsa, and
examined under oil immersion for malaria parasites.
Placental blood was obtained by cutting into the maternal
side of the placenta and placing collected blood on a slide.
A thick film was considered negative if 100 microscopic
fields showed no parasites. Malaria parasites and leuko-
cytes were counted in the same fields until 300 leukocytes
were counted. Parasite densities were estimated by using
an assumed count of 8,000 leukocytes/µL blood. 
Blood samples were collected into EDTA tubes. At
delivery, blood was collected from mothers of enrolled
infants to assess viral load, whether syphilis was present,
and hemoglobin level. One month postpartum, maternal
venous blood was collected to determine counts of CD4-
and CD8-positive T-lymphocytes (CD4+ and CD8+).
Capillary blood was collected from infants by a heel prick
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testing. Plasma was separated from blood samples and
stored at –70°C. 
Infant HIV testing was done by polymerase chain reac-
tion (PCR) of proviral DNA extracted from peripheral
blood mononuclear cells (27). HIV testing of pregnant
women used two rapid test methods: an initial Serostrip
HIV-1/2 (Saliva Diagnostic Systems Pte Ltd, Singapore)
and a confirmatory Capillus HIV-1/HIV-2 (Cambridge
Diagnostics, Wicklow, Ireland) on all Serostrip-positive
samples. Sequential testing of samples using both methods
has a high sensitivity and specificity (Richard W. Steketee,
pers. comm.). Western blot was performed on discordant
samples. 
Maternal CD4+ and CD8+ counts were assessed by
using commercial, dual-label monoclonal antibodies
(Becton-Dickinson Immunocytometry, San Jose, CA) and
standard fluorescent-activated cell sorting (FACScan,
Becton-Dickinson) analysis following whole-blood lysis
(28). Maternal HIV-1 viral load was determined by the
Roche Amplicor HIV-1 monitor test version 1.0 (Roche
Diagnostics, Indianapolis, IN), with a quantification limit
of 400 viral copies per milliliter.
Syphilis antibodies were detected by venereal disease
research laboratory (VDRL) slide test (EUROTEX-
VDRL, Euromedi equip ltd., West Harrow, UK).
Hemoglobin was measured to the nearest 0.1 g/dL using a
Hemocue machine (Mission Viejo, CA).  
Definitions 
An uncomplicated pregnancy was defined as a pregnan-
cy without the presence of AIDS-defining symptoms,
hypertension, preeclampsia, polyhydramnios, abnormal
fetal presentation, history of a cesarean section, hemor-
rhage, or repeated spontaneous abortions (>2). Placental
parasitemia was defined as any plasmodial asexual form
detected on a thick film. Maternal HIV infection was
defined as a positive result on both rapid tests; women not
reactive with the initial Serostrip HIV-1/2 test were consid-
ered HIV uninfected. Women whose serostatus could not
be determined (i.e., those with discordant results on the
two rapid tests and an indeterminate status with Western
blot) were excluded from analysis. Newborns were classi-
fied as normal birth weight if they weighed >2,500 g,
regardless of gestational age, and low birth weight if they
weighed <2,500 g. Preterm delivery was defined as occur-
ring at <37 weeks of gestation. Small for gestational age
was defined as sex-specific birth weight <10th percentile
for weight-for-gestational-age (29). 
Determining Infant HIV Status
An algorithm was developed to describe the perinatal
HIV infection status of infants. Infants were classified as
having acquired HIV infection perinatally (e.g., in utero or
during labor and delivery) if they met the following condi-
tions: 1) died and by the time of death had >2 consecutive
positive HIV PCR tests, the first of which was at <4
months of age; 2) were lost to follow-up but had had >3
consecutive positive PCR results, the first of which was at
<4 months of age; 3) remained alive with continued and
consistent positive PCR results, the first of which was at
<4 months of age. Infants were considered negative for
perinatally acquired HIV if they had >3 PCR tests per-
formed on them, and all tests were negative, with at least
one of the negative tests at >4 months of age. Because
infants had to be >4 months old to be classified as unin-
fected, those who died or were lost to follow-up before 4
months of age were excluded. Infants who acquired HIV at
>5 months of age were considered to have acquired HIV
postnatally and were included as nontransmitters from the
perinatal perspective. Infants for whom we had insufficient
PCR data to determine their status were classified as inde-
terminate and were excluded. Mothers of infected infants
were classified as transmitters and those of uninfected
infants as nontransmitters. 
Data Analysis and Statistical Methods 
Univariate Analysis
Plasma virus levels load below the limit of quantifica-
tion (400 copies/µL) were assigned a value of 200
copies/µL; plasma viral load results were then log10-trans-
formed. We defined high-density placental parasitemia as
>10,000 parasites/µL, which corresponded approximately
to the uppermost quintile of parasite density. Univariate
analyses were performed by using χ2 or Fisher exact tests
(for cross-tabulations with an expected value in any cell
<5) to compare proportions for categorical variables; t tests
were used to compare normally distributed continuous
variables. Relative risks (RRs) were computed with their
95% confidence interval (CI) to measure the strength of
the associations between potential risk factors and perina-
tal MTCT.
Multivariate Analysis
To evaluate the effect of placental malaria on perinatal
MTCT, a Poisson log-linear model containing placental
malaria and maternal viral load as primary predictor vari-
ables was constructed by using backward elimination;
adjusted RRs were computed. An interaction term between
placental malaria density and maternal viral load was sig-
nificant (p = 0.02) and was retained in the model. Because
women with and without placental malaria may have dif-
ferent risk factors for perinatal MTCT, we fit three separate
multivariate models: all study women, women without pla-
cental malaria, and women with placental malaria. All tests
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cant. Analysis was done using STATA (StataCorp. 2001.
Stata Statistical Software: Release 7.0 College Station,
TX) and SAS (Version 8.0, SAS Institute, Cary, NC).
Results
Study Population
A total of 829 mother-infant pairs were enrolled; 317
(38.2%) infants with incomplete follow-up or indetermi-
nate HIV status were excluded, leaving 512 mother-infant
pairs. Included and excluded women did not differ in age,
level of education, mean maternal viral load, mean CD4+
counts, malaria rates, high-density malaria rates, propor-
tion of low birth order (i.e., gravida <2 versus >3), and
rates of episiotomy or perineal tear. However, excluded
women were more likely to have infants born with low
birth weight (9.1% versus 5.5%, p = 0.04). The baseline
characteristics of the 512 women included in the analysis
are shown in Table 1. Among these 512 women, 128
(25.0%) had placental malaria and 353 (84.4%) had ane-
mia (hemoglobin <11 g/dL).
Correlates of Perinatal MTCT
Of 512 mothers, 102 (19.9%) transmitted HIV to their
infants perinatally. High maternal viral load (>10,000 viral
copies/µL) and low CD4+ count (<200 cells/µL) were sig-
nificantly associated with perinatal MTCT (Table 2).
When analyzed as continuous variables, transmitting
mothers had higher geometric mean viral loads than non-
transmitting mothers (7,083 versus 1,378 copies/µL;
p<0.001) and low mean CD4+ count (511 versus 657
cells/µL; p<0.001). Other characteristics significantly
associated with perinatal MTCT included episiotomy or
perineal tear, low birth weight or small-for-gestational-age
infants, and being of low birth order (primigravid or
secundigravid).
Maternal peripheral parasitemia at delivery was not
associated with MTCT; however, placental malaria was
associated with a 40% reduction in the risk for perinatal
MTCT (RR 0.6, 95% CI 0.4 to 1.0, p = 0.05) (Table 2).
Compared to women without placental malaria (perinatal
MTCT rate = 21.9%), women with placental parasitemia at
lower densities (<10,000 parasites/µL) had a lower rate of
perinatal MTCT(11.5%); this was not true for women with
646 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004
RESEARCH
Table 1. Characteristics of HIV-positive women and their newborns participating in perinatal HIV transmission study, Kisumu, western 
Kenya, 1996–2001
a 
Characteristic  All women (N = 512)
b 
Maternal sociodemographic   
Luo ethnicity  86.5% 
Mean age (y) ± SD  22.4±4.4 (range 14–39) 
Mean gravidity ± SD  2.3±1.4 (range 1–9) 
Primigravid  35.9% 
Completed primary education (≥8 y)  68.0% (n = 510) 
No salaried employment  74.3% 
Married  78.4% 
History of fever and treatment for malaria   
History of fever previous week at screening  23.2% (n = 509) 
History of fever a fortnight before delivery  28.0% (n = 511) 
Treated with antimalarials in current pregnancy  30.9% 
Treated with chloroquine during current pregnancy  16.6% 
Axillary temperature ≥37.5°C at screening  2.9% (n = 455) 
Laboratory   
VDRL-positive  7.3% (n = 385) 
Hemoglobin <11 g/dL at screening  84.4% (n = 418) 
Hemoglobin <8 g/dL at screening  20.6% (n = 418) 
Mean maternal CD4+ count (% <200 cells/µL) 1 mo postpartum  629±334 (4.7%) (n = 464) 
Mean maternal log10 viral load at delivery (% below detection limit of 400 copies)  3.28±0.92 (33.0%) (n = 455) 
Peripheral parasitemia at screening  21.9% (n = 415) 
Peripheral parasitemia at delivery  19.7% (n = 497) 
Placental malaria  25.0% 
Delivery   
Episiotomy or perineal tear  36.4% 
Mean duration of rupture of membranes ± SD (% >4 hours)  2.7±6.2 (15.4%) 
Newborn   
Mean birth weight (% low birth weight)  3144±420 (5.5%) 
Prematurity (<37 wks completed gestation)  8.2% 
Maternal HIV transmitters   102 (19.9%) 
aVDRL, venereal disease research laboratory slide test. 
bIf characteristic not measured for all 512 women, n is given in parentheses. higher-density placental parasitemia (>10,000
parasites/µL, perinatal MTCT rate = 25.0%), who repre-
sented approximately one fifth of women with placental
malaria. Among women with viral load below the detec-
tion level, perinatal MTCT occurred in none of 35 mothers
with malaria, compared to 10 (8.7%) of 115 mothers with-
out malaria (p = 0.12). 
Multivariate Analysis of Risk Factors 
for Perinatal MTCT
Among all study women, high maternal viral load and
episiotomy or perineal tear were independent risk factors,
and low-density (but not high-density) malaria was an
independent protective factor for perinatal MTCT. Among
women without microscopically detectable placental
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Table 2. Risk factors associated with perinatal HIV infection by maternal viral, immunologic, obstetric, and other factors (univariate 
analysis), western Kenya, 1996–2001 
Variable  No. studied  No. infected (%)  Relative risk (95% confidence interval)  p 
Viral load >10,000       
No  358  50 (14.0)     
Yes  97  40 (41.2)  3.0 (2.1 to 4.2)  <0.001 
CD4+ cells <200       
No  442  74 (16.7)     
Yes  22  13 (59.1)  3.5 (2.4 to 5.3)  <0.001 
Hemoglobin <8 g/dL at screening       
No  332  58 (17.5)     
Yes  86  22 (25.6)  1.5 (1.0 to 2.3)  0.09 
3rd-trimester maternal parasitemia       
No  324  64 (19.8)     
Yes  91  15 (16.5)  0.8 (0.5 to 1.4)  0.48 
Maternal parasitemia at delivery       
No  399  83 (20.8)     
Yes  98  15 (15.3)  0.7 (0.4 to 1.2)  0.22 
Placental malaria       
No  384  84 (21.9)     
Yes  128  18 (14.1)  0.6 (0.4 to 1.0)  0.05 
Ever been treated for tuberculosis       
No  496  98 (19.8)     
Yes  13  4 (30.8)  1.6 (0.7 to 3.6)  0.33 
Treated with chloroquine during pregnancy       
No  427  88 (20.6)     
Yes  85  14 (16.5)  0.8 (0.5 to 1.3)  0.38 
Treated for vaginal discharge       
No  477  93 (19.5)     
Yes  32  9 (28.1)  1.7 (0.8 to 2.6)  0.24 
Hospitalized during current pregnancy       
No  472  95 (20.1)     
Yes  39  7 (18.0)  0.9 (0.4 to 1.8)  0.74 
History of fever 2 wks before delivery       
No  368  70 (19.0)     
Yes  143  32 (22.4)  1.2 (0.8 to 1.7)  0.39 
Episiotomy or perineal tear       
No  325  56 (17.2)     
Yes  186  46 (24.7)  1.4 (1.0 to 2.0)  0.04 
Primi- or secundigravid       
No  190  26 (13.7)     
Yes  322  76 (23.6)  1.7 (1.1 to 2.5)  0.007 
Low birth weight       
No  484  91 (18.8)     
Yes  28  11 (39.3)  2.1 (1.3 to 3.4)  0.008 
Prematurity       
No  468  92 (19.7)     
Yes  42  10 (23.8)  1.2 (0.7 to 2.1)  0.52 
Small for gestational age       
No  444  83 (18.7)     
Yes  66  19 (28.8)  1.5 (1.0 to 2.4)  0.06 malaria, high maternal viral load, gravidity <2, and low
birth weight in the newborn were significant risk factors or
markers for perinatal MTCT. Among women with placen-
tal malaria (where perinatal MTCT was overall lower than
in the malaria-negative women), high maternal viral load,
episiotomy or perineal tear, and high-density placental
infection were significant risk factors for perinatal MTCT
(Table 3). In both the multivariate models for the entire
population and women with placental malaria, significant
interaction was found between viral load and placental
malaria density. 
In further examination of the interaction between
maternal viral load and placental malaria, we found no sig-
nificant differences in the frequency of episiotomy or per-
ineal tear, mean CD4+ count, mean maternal hemoglobin
level, mean birth weight, and frequency of small-for-ges-
tational-age neonates among women without malaria,
those with low-density placental malaria, and those with
high-density placental malaria. Women with placental
malaria were of lower mean gravidity than women without
malaria (2.1 vs. 2.4, p = 0.03). Geometric mean maternal
viral load was slightly higher in women with low-density
placental malaria (2,226 copies/µL) and was nearly
twofold higher in women with high-density placental
malaria (3,390 copies/µL) than the viral load in women
without placental malaria (1,774 copies/µL); however,
these differences were not significant (p = 0.14). Viral load
was significantly higher among women with peripheral
malaria parasitemia at delivery (2,979 copies/µL) than
among women without (1,725 copies/µL, p = 0.03). As
shown in Table 4, the geometric mean viral load was five-
fold higher in transmitters than in nontransmitters. While
in women without placental malaria the geometric mean
viral load in transmitters was fourfold higher than in non-
transmitters, among women with malaria, the geometric
mean viral load was 25-fold higher in transmitters than in
nontransmitters. Among transmitting women, those with
placental malaria had an eightfold higher geometric mean
viral load than those women without placental malaria.
These associations were further evaluated in models
comparing the relative risk for perinatal transmission
between the three groups with placental malaria at various
levels of maternal viral load. Low-density placental para-
sitemia was associated with significant protection for peri-
natal MTCT at the lower viral load levels, but not at higher
viral load levels (Figure 1). When women with low- and
high-density parasitemia were compared (Figure 2), high-
density placental parasitemia was associated with
increased risk for perinatal MTCT but only at the higher
viral load levels.
Discussion
This evaluation of perinatal HIV transmission in a
malarious area of western Kenya demonstrated that
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Table 4. Association between maternal viral load and placental malaria among women who did and did not transmit HIV perinatally to 
their infants, western Kenya, 1996–2001 
  Geometric mean HIV viral load
a   
  Transmitters  Nontransmitters  p value
b 
All women (N = 455)  7,083  1,378  <0.001 
Placental malaria–positive  41,217  1,675  <0.001 
Placental malaria–negative  5,402  1,286  <0.001 
p value  0.002  0.26   
aViral load expressed as copies per microliter of plasma. 
bp from
 t test. 
Table 3. Multivariate analysis of risk factors for perinatal HIV transmission, western Kenya, 1996–2001 
Adjusted relative risks (ARR) for perinatal HIV transmission
a 
All women,
b  N = 454  Placental malaria–negative, n = 348  Placental malaria–positive,
b n = 107 
 
ARR (95% CI)  p  ARR (95% CI)  p  ARR (95% CI)  p 
Log10 viral load  1.8 (1.6 to 2.1)  <0.001  1.7 (1.4 to 2.0)  <0.001  3.5 (2.5 to 4.8)  <0.001 
Episiotomy or perineal tear  1.6 (1.2 to 2.1)  0.004  –    4.8 (2.3 to 9.7)  <0.001 
Low birth weight  –    1.9 (1.1 to 3.2)  0.03  –   
Gravidity <3 versus >3  –    1.8 (1.2 to 2.8)  0.003  –   
Placental malaria status             
Negative  Reference
c    N/A       
<10,000 parasites/µL  0.4 (0.2 to 0.6)
b  <0.001  N/A    Reference   
>10,000 parasites/µL  0.7 (0.3 to 21.5)
b  NS  N/A    2.0 (1.1 to 3.9)  0.04 
a–, factor was not retained in the final model; CI, confidence interval; N/A, not applicable; NS, not significant. 
bA significant interaction was found between viral load and placental malaria density (p
 = 0.02) in these analyses. The effect of this interaction on the relative risk for 
placental malaria is shown in Figures 1 and 2. All relative risks given in this table do not include this interaction but give a weighted average of the placental malaria 
effect at various levels of viral load. 
cAn alternative model, in which placental malaria was fit as a binary variable (positive or negative), showed that placental malaria was protective for perinatal HIV 
transmission (relative risk 0.4, 95% CI 0.3 to 0.7, p < 0.001). In that model, log10 viral load and episiotomy or perineal tear remain independent risk factors. approximately 20% of infants born to HIV-infected moth-
ers acquired HIV by 4 months of age, similar to rates
reported in other sub-Saharan African settings (30–32).
Consistent with other studies, we found that maternal viral
load in peripheral blood at the time of delivery and having
an episiotomy or perineal tear were risk factors for perina-
tal MTCT (33,34). Contrary to our expectations, we
observed that women with placental malaria had lower
rates of perinatal MTCT than women without placental
malaria. However, women with high-density malaria had
significantly higher rates of perinatal MTCT than para-
sitemic women with low-density malaria. In additional
models, only low placental parasite density (1–9,999 para-
sites/µL of blood) was associated with protection from
perinatal MTCT; high-density placental infection was
either a risk factor for perinatal MTCT (in the model eval-
uating only women with malaria) or it was a neutral factor
(in the model evaluating all women). Maternal viral load
was slightly higher in women with high-density placental
malaria, and, among transmitting women, mean viral load
was eightfold higher if the woman had concurrent placen-
tal malaria, consistent with the suggestion that high-densi-
ty malaria may be an important stimulus of viral
replication (10–12). 
Our study had some important limitations. First, only
healthy women were screened for this study; no women
with AIDS or any known underlying chronic illness were
enrolled. Although this eliminated potential conditions that
could have complicated the analysis (e.g., a higher likeli-
hood of additional concurrent infections), it restricted our
study population to the “healthiest” women with HIV and
likely resulted in an underestimate of the overall rate of
perinatal MTCT in our study area. Some infants catego-
rized as having acquired HIV through perinatal transmis-
sion may have actually acquired it through early
breastfeeding transmission. However, including these
infants would likely bias the results toward underestimat-
ing the magnitude of the observed risks. Our measurement
of placental malaria was limited to microscopy examina-
tion of placental smears and could have been inexact; those
with no evidence of malaria may have had very low-densi-
ty infection and may have been misclassified as having no
malaria. Such misclassification would be expected to bias
our findings toward the null hypothesis. Because placental
malaria can cause an inflammatory response in the placen-
ta, the use of leukocyte count to calculate parasite density
may have resulted in an underestimation. However, our
cutoff of 10,000 parasites/µL for high-density placental
parasitemia is essentially a relative measure based on the
upper quintile of densities; therefore, we do not think that
our estimation technique would have introduced any bias.
Finally, in a study such as ours, loss to follow-up always
has the potential to introduce bias. Approximately one
third of infants enrolled in our study were lost to follow-
up. However, as noted, these mothers and infants were
generally similar to the study population included in our
analysis, and we were unable to detect biases that would
have affected our analysis.
Our observation of an association between low-density
placental malaria and reduced perinatal MTCT has several
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Figure 1. The effect of viral load and placental malaria density on
risk for perinatal HIV transmission, western Kenya, 1996–2001.
Women with low- (<10,000 parasites/µL, circles) and high-
(>10,000 parasites/µL, squares) density placental malaria are
compared with women without placental malaria (represented by
the horizontal dashed line). RR, relative risk. Error bars refer to
95% confidence interval.
Figure 2. The effect of viral load and high-density placental malar-
ia on risk for perinatal HIV transmission, western Kenya,
1996–2001. Women with high-density placental malaria (>10,000
parasites/µL) are compared to those with low-density placental
malaria (<10,000 parasites/µL, represented by the horizontal
dashed line). RR, relative risk. Error bars refer to 95% confidence
interval.possible explanations. First, over 16% of women reported
self-treatment (typically for fever) with chloroquine during
pregnancy. High-grade chloroquine resistance in this area
is widespread; its use is unlikely to clear placental infec-
tions, but it may reduce parasite densities. Chloroquine is
known to have anti-HIV properties and to reduce HIV-1
replication and viral loads in adults (35,36) and as such
could potentially reduce the risk for perinatal MTCT.
Although we identified no differences in the proportion of
women with or without placental malaria who used chloro-
quine, and no association was found between chloroquine
usage and MTCT, women identified as having placental
malaria may have used chloroquine more frequently and at
higher doses (information that was not collected) than
women without placental malaria. A second possibility is
that some of the women classified as having placentas neg-
ative for malaria parasites may actually have had low-level
chronic malaria associated with inflammation and
increased HIV replication. In contrast, women classified as
having low-density malaria may have had recent malaria
with minimal inflammatory response and thus no increase
in HIV replication. Unfortunately, blood films are not
capable of detecting inflammatory responses.
A more likely explanation is that a balance exists in the
uterine-placental-fetal environment among malaria-
induced antigen stimulation, HIV viral replication, mater-
nal host immune response to both malaria and HIV, and the
likelihood of MTCT. Although high viral load has been
shown to increase the risk for MTCT, no more than half of
exposed infants, even at high maternal viral load, become
infected with HIV-1. These data suggest that other systemic
or placental factors must be important in preventing HIV-1
transmission. Recent studies suggest that selected
cytokines and hormones potentially affect HIV-1 transpla-
cental transmission and that both innate and acquired pro-
tection play a role in MTCT (37). First, malaria is known
to induce disequilibrium in the balance between Th1 and
Th2 responses, favoring the Th1 pathway (38–40). T-
helper responses are known to control HIV replication;
hence, inducing Th1 response in the placental compartment
could lead to reduced HIV-1 replication (41,42). Indeed, a
moderate increase was found in the Th1 cytokine interfer-
on-γ response in the intervillous blood mononuclear cell
responses of HIV-positive mothers with placental malaria
as compared to HIV-positive mothers without placental
malaria (43). Second, leukemia inhibitory factor induces a
potent inhibition of HIV replication, and this cytokine is
upregulated in placentas of women who do not transmit
HIV (44). Malarial antigens may induce production of
leukemia inhibitory factor that results in reduced rates of
perinatal MTCT. Third, malarial antigen may result in
altered chemokine production, which in turn can block
chemokine receptors necessary for cellular HIV entry (45).
Recent immunologic studies conducted in a group of
women who participated in this cohort showed that
macrophage inflammatory protein (MIP)-1β, a chemokine
known to block the entry of HIV-1, was significantly ele-
vated in the intervillous blood plasma of women with pla-
cental malaria irrespective of their HIV status. In women
with concurrent HIV and placental malaria, the intervillous
blood plasma levels of MIP-1β were significantly elevated
compared to HIV-negative women with placental malaria
and HIV-positive women without placental malaria (46).
Thus, a complex balance of antigen stimulus and immune
response may occur in the placenta, as demonstrated in
recent studies focusing on the placental intervillous blood
responses (38–40,43,46). In this scenario, active placental
malaria might lead to one of the local immune responses
described. This response may control the density of para-
sitemia and may also provide immune control that limits
perinatal MTCT. For most women with placental malaria
(approximately 80% in our study), this resultant balance
leads to “protection” with controlled (low-density) malaria
and reduced perinatal MTCT. For a minority of women
with malaria (approximately 20% in our study), the balance
is tilted to inadequate control of placental malaria (i.e.,
higher density of malaria parasites with concomitant
increased antigen stimulation of viral replication and high-
er viral load) and higher rates of perinatal MTCT. This
finding is consistent with our observation that women with
high-density placental malaria do have higher rates of peri-
natal MTCT than women with low-density placental
malaria, but that they require much higher viral loads to
achieve this transmission. Our findings suggest complex
relationships between malaria, viral load, and perinatal
MTCT. These findings will need to be confirmed and
expanded upon in further research in different settings. 
The finding of reduced perinatal MTCT in the presence
of low-density, but not high-density, placental malaria does
not suggest altering existing recommendations for the use
of intermittent preventive antimalarial treatment in preg-
nant women in malarious areas of Africa (47). For most
dually (malaria and HIV) infected women, the overall out-
come would have modest benefit in reducing perinatal
MTCT, but for the minority with insufficiently controlled
infections, perinatal MTCT would be increased. At this
point, we cannot differentiate in advance which women
will end up in which group. The important benefit of anti-
malarial treatment may be to reduce the likelihood of
women having high-density placental malaria and in also
helping reduce the other known adverse effects of malaria
during pregnancy, including anemia, low birth weight, and
prematurity (1).
As noted earlier, this study was carried out in Kenya in
a changing environment of perinatal HIV and malaria pre-
vention and has been transformed into a program deliver-
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infected women and a system to support providing inter-
mittent preventive antimalarial treatment during
pregnancy according to the newly adopted national policy
(48). As more countries adopt policies of antiretroviral and
antimalarial interventions in pregnancy, the interrelation-
ship and ultimate benefit of these two interventions need to
continue to be evaluated.
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